These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29595326)

  • 1. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
    Blonde L; Patel C; Bookhart B; Pfeifer M; Chen YW; Wu B
    Curr Med Res Opin; 2018 Jun; 34(6):1143-1152. PubMed ID: 29595326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.
    Blonde L; Patel C; Wu B; Chen YW; Pericone CD; Bookhart B
    Adv Ther; 2021 Jan; 38(1):594-606. PubMed ID: 33180317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
    Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study of glycemic control in canagliflozin treated patients.
    Meckley LM; Miyasato G; Kokkotos F; Bumbaugh J; Bailey RA
    Curr Med Res Opin; 2015 Aug; 31(8):1479-86. PubMed ID: 25986535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
    Thayer S; Chow W; Korrer S; Aguilar R
    Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HbA
    Thayer S; Aguilar R; Korrer S; Chow W
    Clin Ther; 2017 Oct; 39(10):2061-2072. PubMed ID: 28943114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
    Buysman EK; Anderson A; Bacchus S; Ingham M
    Adv Ther; 2017 Apr; 34(4):937-953. PubMed ID: 28251556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J; Divino V; Burudpakdee C
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
    Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
    J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    Curr Med Res Opin; 2015 Jan; 31(1):137-43. PubMed ID: 25356602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
    Brown RE; Gupta N; Aronson R
    Diabetes Technol Ther; 2017 Nov; 19(11):685-691. PubMed ID: 28829163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin (Invokana). A "me-too" of the dangerous dapagliflozin.
    Prescrire Int; 2015 Feb; 24(157):33-5. PubMed ID: 25802910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.